Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection.

Knuschke T, Sokolova V, Rotan O, Wadwa M, Tenbusch M, Hansen W, Staeheli P, Epple M, Buer J, Westendorf AM.

J Immunol. 2013 Jun 15;190(12):6221-9. doi: 10.4049/jimmunol.1202654. Epub 2013 May 10.

2.

Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.

Okamoto S, Matsuura M, Akagi T, Akashi M, Tanimoto T, Ishikawa T, Takahashi M, Yamanishi K, Mori Y.

Vaccine. 2009 Sep 25;27(42):5896-905. doi: 10.1016/j.vaccine.2009.07.037. Epub 2009 Jul 31.

PMID:
19647814
3.

Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.

Okamoto S, Yoshii H, Akagi T, Akashi M, Ishikawa T, Okuno Y, Takahashi M, Yamanishi K, Mori Y.

Vaccine. 2007 Nov 28;25(49):8270-8. Epub 2007 Oct 11.

PMID:
17977633
4.
5.

A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.

Hessel A, Schwendinger M, Fritz D, Coulibaly S, Holzer GW, Sabarth N, Kistner O, Wodal W, Kerschbaum A, Savidis-Dacho H, Crowe BA, Kreil TR, Barrett PN, Falkner FG.

PLoS One. 2010 Aug 16;5(8):e12217. doi: 10.1371/journal.pone.0012217.

6.

Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.

Wang X, Uto T, Akagi T, Akashi M, Baba M.

J Virol. 2007 Sep;81(18):10009-16. Epub 2007 Jul 3.

7.

Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.

Gupta NK, Tomar P, Sharma V, Dixit VK.

Vaccine. 2011 Nov 8;29(48):9026-37. doi: 10.1016/j.vaccine.2011.09.033. Epub 2011 Sep 20.

PMID:
21939718
8.

A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice.

Zheng L, Wang F, Yang Z, Chen J, Chang H, Chen Z.

BMC Infect Dis. 2009 Feb 12;9:17. doi: 10.1186/1471-2334-9-17.

9.

A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model.

Jamali A, Sabahi F, Bamdad T, Hashemi H, Mahboudi F, Kheiri MT.

Clin Vaccine Immunol. 2010 Apr;17(4):683-7. doi: 10.1128/CVI.00445-09. Epub 2010 Feb 17.

10.

Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.

Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H.

J Med Virol. 2010 Jan;82(1):128-37. doi: 10.1002/jmv.21670.

PMID:
19950232
12.

Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.

Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, Mokhtari-Azad T.

PLoS One. 2012;7(9):e45765. doi: 10.1371/journal.pone.0045765. Epub 2012 Sep 24.

13.

Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines.

Lau YF, Deliyannis G, Zeng W, Mansell A, Jackson DC, Brown LE.

Int Immunol. 2006 Dec;18(12):1801-13. Epub 2006 Oct 31.

PMID:
17077175
14.

The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that provide potent protection from influenza A virus.

Suda T, Kawano M, Nogi Y, Ohno N, Akatsuka T, Matsui M.

Antiviral Res. 2011 Sep;91(3):252-8. doi: 10.1016/j.antiviral.2011.06.008. Epub 2011 Jun 21.

PMID:
21722671
15.

Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity.

Uto T, Wang X, Sato K, Haraguchi M, Akagi T, Akashi M, Baba M.

J Immunol. 2007 Mar 1;178(5):2979-86.

16.

A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza.

Vajdy M, Baudner B, Del Giudice G, O'Hagan D.

Clin Immunol. 2007 May;123(2):166-75. Epub 2007 Mar 8.

PMID:
17349825
17.
18.

Immune responses and protection efficacy of a recombinant swinepox virus expressing HA1 against swine H3N2 influenza virus in mice and pigs.

Xu J, Huang D, Liu S, Lin H, Zhu H, Liu B, Lu C.

Virus Res. 2012 Aug;167(2):188-95. doi: 10.1016/j.virusres.2012.04.014. Epub 2012 May 11.

PMID:
22584406
19.

N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.

Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJ, Jiskoot W.

Vaccine. 2007 Jan 2;25(1):144-53. Epub 2006 Aug 4.

PMID:
16973248
20.

Prophylactic and therapeutic vaccination with a nanoparticle-based peptide vaccine induces efficient protective immunity during acute and chronic retroviral infection.

Knuschke T, Bayer W, Rotan O, Sokolova V, Wadwa M, Kirschning CJ, Hansen W, Dittmer U, Epple M, Buer J, Westendorf AM.

Nanomedicine. 2014 Nov;10(8):1787-98. doi: 10.1016/j.nano.2014.06.014. Epub 2014 Jul 9.

PMID:
25014891

Supplemental Content

Support Center